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Abstract Single nucleotide polymorphisms (SNPs) in the
multiple drug resistance protein 1 (MRP1) and P-glycoprotein
1 (MDR1) genes modulate their ability to mediate drug
resistance. We therefore sought to retrospectively evaluate
their influence on outcomes in relapsed and/or refractory
myeloma patients treated with bortezomib or bortezomib with
pegylated liposomal doxorubicin (PLD). The MRP1/R723Q
polymorphism was found in five subjects among the 279
patient study population, all of whom received PLD+
bortezomib. Its presence was associated with a longer time
to progression (TTP; median 330 vs. 129 days; p=0.0008),
progression-free survival (PFS; median 338 vs. 129 days;
p=0.0006), and overall survival (p=0.0045). MDR1/3435
(C>T), which was in Hardy–Weinberg equilibrium,
showed a trend of association with PFS (p=0.0578),
response rate (p=0.0782) and TTP (p=0.0923) in PLD+
bortezomib patients, though no correlation was found in
the bortezomib arm. In a recessive genetic model,
MDR1/3435 T was significantly associated with a better
TTP (p=0.0405) and PFS (p=0.0186) in PLD+bortezomib
patients. These findings suggest a potential role for MRP1
and MDR1 SNPs in modulating the long-term outcome of
relapsed and/or refractory myeloma patients treated with
PLD+bortezomib. Moreover, they support prospective stud-
ies to determine if such data could be used to tailor therapy
to the genetic makeup of individual patients.
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Introduction
Prior to the development of novel biologically based
therapies for multiple myeloma, relapses after successive
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treatment regimens resulted in progressively shorter
response durations [1], which in part reflected the
occurrence of drug resistance. Recently, the advent of
novel therapies, including regimens incorporating either
proteasome inhibitors [2] or immunomodulatory agents
[3], has significantly improved the median survival for
patients with advanced disease [4]. To further improve the
outcome of patients in this setting, combination regimens
with both conventional drugs and novel agents are applied.
One example is that of the immunomodulatory agent
lenalidomide which, when combined with dexamethasone,
is superior to corticosteroids alone [5, 6]. A second such
combination regimen incorporates the proteasome inhibi-
tor bortezomib (VELCADE®) with pegylated liposomal
doxorubicin (PLD; DOXIL®) [7, 8]. In an international
randomized phase III trial, PLD with bortezomib was
superior to bortezomib monotherapy for relapsed or
refractory multiple myeloma, in that it significantly
improved the median time to progression, duration of
response, and 15-month survival rate [9].
Although several prognostic factors have been identified
for newly diagnosed myeloma, and for patients with relapsed
and/or refractory disease [10, 11], genetic factors that may
influence responses to therapy, especially in the latter setting,
have been less well defined. One possible factor is variant
multiple drug-resistant (MDR) genotypes, which have been
associated with differential expression of the MDR1 gene
and its 170-kDa protein product, P-glycoprotein, also known
as the ATP-binding cassette Transporter B1 (ABCB1). MDR1
is a transmembrane protein that acts as an energy-dependent
drug efflux pump for chemotherapeutic drugs commonly used
against hematologic malignancies [12]. Therefore, inborn
genetic variations leading to a modified expression of these
transporters could influence patient outcomes [13]. In a
previous study of the effect of the MDR1 C3435T single
nucleotide polymorphism (SNP) in myeloma patients treated
with dexamethasone, doxorubicin and vincristine (DAV),
followed by autologous stem cell transplantation (SCT),
this SNP was predictive of the overall survival (OS), but
did not modify the response to treatment [14]. Indeed, the
three most common MDR1 SNPs, C3435T, C1236T, and
G2677T/A, have been found to influence the outcomes of
myeloma patients treated with DAV and then SCT [15].
Moreover, overexpression of MDR1 in myeloma cells
might contribute to treatment failure in patients receiving
proteasome inhibitors [16], since P-glycoprotein conferred
bortezomib resistance in some preclinical models [17, 18].
Therapy resistance may also be mediated by another
multidrug-resistance associated protein, also known as
ATP-binding cassette, subfamily C, member 1 (MRP1, or
ABCC1). Like MDR1, it confers resistance to anthracyclines
[19], and because the MRP1 mutation Arg723Gln has an
effect on MRP1 expression and trafficking, it significantly
reduced MRP1-mediated resistance to a wide spectrum of
drugs [20]. Previous studies investigated whether efflux
pump inhibitors would modulate bortezomib activity, and
the combination of MDR1-specific or MRP1-specific inhib-
itors did enhance the antitumor effects of bortezomib [21].
To further evaluate the possibility that SNPs in these
multidrug resistance genes could influence long-term out-
comes in PLD+bortezomib-treated patients, we analyzed
DNA samples from patients who were treated in a phase III
study comparing bortezomib alone with PLD+bortezomib.
Specifically, we tested for the presence of the MDR1
polymorphisms 1236C>T, 2677G>W (W=T or A), and
3435C>T and the MRP1 gene R723Q polymorphism.
These were then compared to study endpoints, including
time to progression (TTP), progression-free survival (PFS),
and OS, and comparisons were made between the two
treatment arms of the study.
Methods
Patients
The current analysis involved patients from a previously
reported randomized, parallel-group, open-label, multicenter,
phase III study (DOXIL-MMY-3001) [9]. This trial compared
PLD plus bortezomib with bortezomib alone in 646
bortezomib-naïve patients with multiple myeloma who had
suffered disease progression after an initial response to at
least one line of prior therapy or who were refractory to
initial treatment. Patients who had received prior doxorubicin,
PLD, or other anthracyclines were eligible providing that they
had not previously progressed on that regimen. However,
patients were excluded if they had received a cumulative
anthracycline dose of more than 240 mg/m2 or had a left
ventricular ejection fraction below normal institutional
limits. Review boards at participating institutions approved
the study, which was conducted according to the Declaration
of Helsinki, the International Conference on Harmonization,
and the Guidelines for Good Clinical Practice. All
patients provided written, informed consent and were
randomized to receive either PLD at a dose of 30 mg/m2
as a 1-h intravenous infusion on day4 and bortezomib at a
dose of 1.3 mg/m2 as a 5-s intravenous bolus dose on days
1, 4, 8, and 11 of every 21-day cycle or bortezomib alone
at a dose of 1.3 mg/m2 on the same dose and schedule.
Treatment continued for at least two cycles beyond a
complete remission (CR), or until disease progression or
unacceptable toxicity occurred, for a maximum of eight
cycles. However, patients with levels of paraprotein that
continued to decrease by >25% from course to course after
eight cycles were allowed to continue treatment for as long
as treatment was tolerated.
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Analyses
The objectives of the pharmacogenomic analyses were to
test whether the MDR1 gene polymorphisms—3435C>T
(RefSNP ID rs1045642), 2677G>W (W=T or A; RefSNP
ID rs2032582), and 1236C>T (RefSNP ID rs1128503), and
the MRP1 gene R723Q polymorphism (RefSNP ID
rs4148356), were associated with a different overall response
rate (CR+partial response) and response durability (TTP,
PFS, and OS). MDR1 and MRP1 variants were analyzed
using both the TaqMan® real-time polymerase chain reaction
and by direct sequencing. All subjects in the intention to
treat set who consented to DNA testing, and who produced
at least one useable genotype, were included in the pharma-
cogenomics analysis set. The genotyping was performed by
EPIDAUROS Biotechnologie AG (Bernried, Germany)
according to Good Laboratory Practice Standards. Two types
of controls were introduced in defined, additional positions of
the processing batch: (a) water (=negative control) as an
indicator of contamination and (b) DNAs of defined genotype
(=positive control) as indicators for the assay quality.
Polymorphisms which had a p value of 0.05 or less by
logrank test were classified as “significant.” Summary
statistics for age, sex, race, height, weight, body surface area,
and baseline left ventricular ejection fraction were calculated;
while for continuous variables, the mean, standard deviation,
median, and range were determined. For categorical variables,
the frequency and percent of each category were calculated,
and summary statistics were calculated after stratifying by
treatment group. Hardy–Weinberg equilibrium (HWE) was
tested with an exact test using 10,000 permutations. A severe
deviation from HWE (p<0.001) could be caused by
genotyping error. For each polymorphism, genotype fre-
quencies were tabulated after stratifying by treatment arm,
and the frequency and percentage of subjects with each
endpoint were calculated after stratifying by genotype. The
association of each endpoint and the genotype of each
polymorphism were tested using the exact 2-sided Cochran–
Armitage trend test after stratifying by treatment arm.
Results
Study population
Usable genotype data and clinical data were available for
301 subjects, of whom 279 were Caucasian. Because
genetic transmission patterns differ among racial groups, it
is a general practice to treat each racial group separately in
a genetic analysis. Twenty-two non-Caucasian subjects for
whom data were available in this study belonged to at least
three racial groups (African American, Asian American, and
other). These subject samples were excluded from the
analyses, and from subsequent analyses, since the sample
size was too small to reach statistical significance. As a result,
this report focused on the Caucasian population only (n=279).
Demographic and baseline data from the cohorts that
were treated with either bortezomib or PLD+bortezomib,
and for whom pharmacogenomic data were available, are
shown in Table 1. The characteristics of the baseline
parameters for the pharmacogenomic analysis datasets were
well balanced and were similar to the intent-to-treat cohorts
for the study population as a whole [9].
A Hardy–Weinberg equilibrium test was performed on
all four loci, and both allele frequencies and genotype
frequencies were calculated (Table 2). Since the MDR1
locus has three alleles, the A and T alleles were combined
as W so that this locus could be treated as two alleles. It
was apparent that these four genetic markers were indeed in
Hardy–Weinberg equilibrium. In particular, consistent with
previous reports [15], the three MDR1 variants were fairly
common in trial subjects. However, the MRP1 marker was
close to monoallelic since the minor allele frequency was
extremely low, and the study population contained 274
homozygous wild-type patients, but only five heterozygous
Table 1 Baseline characteristics of the study populations
Variable Category PLD+Bortezomib Bortezomib
Age (Years) n 142 137
Mean (SD) 63.0 (9.61) 62.2 (9.27)
Median 62.0 63.0
Range (37.0, 85.0) (40.0, 84.0)
Height (cm) n 142 137
Mean (SD) 167.2 (12.31) 167.3 (10.85)
Median 169 169
Range (115, 194) (142, 189)
Weight (kg) n 142 137
Mean (SD) 79.0 (16.97) 77.2 (15.31)
Median 76.4 76.0
Range (44.5, 140) (46.0, 129)
Body surface
area (m2)
n 142 137
Mean (SD) 1.9 (0.24) 1.9 (0.23)
Median 1.9 1.9
Range (1.4, 2.5) (1.4, 2.4)
Baseline
LVEF (%)
n 142 134
Mean (SD) 62.6 (7.76) 66.5 (51.33)
Median 62.0 62.0
Range (43.0, 88.0) (48.0, 651)
Sex (n, %) Female 61 (43.0) 49 (35.8)
Male 81 (57.0) 88 (64.2)
cm centimeters, kg kilograms, LVEF left ventricular ejection fraction,
m2 meter squared in body surface area, PLD pegylated liposomal
doxorubicin, SD standard deviation
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patients (Table 2), all of whom were randomized to the
PLD+bortezomib arm of this phase III trial (Table 3).
Influence of MDR1 and MRP1 SNPs
The possible presence of associations between 1236C>T,
2677G>W (W=Tor A), and 3435C>T inMDR1 and R723Q
in MRP1 and the response rate of the bortezomib or PLD+
bortezomib groups, as well as response durability measures,
were then evaluated. Genotype p value was based on
Cochran–Armitage trend test, and allele p value was based
on Fisher’s exact test. Both tests were for responders
(complete+partial responses) versus nonresponders (minor
response+stable disease+progressive disease), and these
response categories were defined according to the European
Bone Marrow Transplantation criteria [22]. In the present
study, the MRP1 gene polymorphism R723Q was signifi-
cantly associated with time to progression (Fig. 1a; p=
0.0008), progression-free survival (Fig. 1b; p=0.0006), and
overall survival (Fig. 1c; p=0.0045) in subjects who
received PLD+bortezomib. With regard to the MDR1 gene
polymorphism at 3435(C>T), this was associated with
progression-free survival (Fig. 2; p=0.0578). Also, this
SNP may have been linked to response rate (p=0.0782)
and time to progression (p=0.0601) in subjects who received
PLD+bortezomib treatment, though neither of these associ-
ations reached the level of statistical significance.
To further investigate the genetic influence of the above
polymorphisms on response, a haplotype analysis was
conducted that combined the three individual MDR1 SNPs
based on their genetic transmission patterns, also known as
linkage disequilibrium. Haplotype analysis indicated that the
three most frequent haplotypes showed a trend of association
with response rate in subjects with relapsed multiple myeloma
who received PLD+bortezomib treatment (p=0.0775), though
not at the level of statistical significance. The most frequent
diplotype that contained 3435 T (i.e. T–W–T/C–G–T or H2/
H3) may have been associated with time to progression (p=
0.0819) and progression-free survival (p=0.0891) in subjects
treated with PLD+bortezomib when compared to the most
frequent diplotype (C–G–C/T–W–T or H1/H2), though not at
the level of statistical significance.
Table 2 Summary statistics of the studied genetic markers
Marker Frequency
minor allele
Hardy–Weinberg
equilibrium p value
n/Genotype frequencies
of homozygous wild type
n/Genotype
frequencies of
heterozygous
n/Genotype frequencies
of homozygous variant
Missing data
MDR1 1236C>T 0.4355 0.6110 91 (0.3262) 133 (0.4767) 55 (0.1971) 0
MDR1 2677G>W 0.4373 0.7430 87 (0.3118) 140 (0.5018) 52 (0.1864) 0
MDR1 3435C>T 0.4910 0.8145 73 (0.2626) 137 (0.4928) 68 (0.2446) 1
MRP1 R723Q 0.0090 0.8800 274 (0.9821) 5 (0.0179) 0 (0) 0
Patient Prior therapies Paraprotein
type and level
Cytogenetics
1 1. Idarubicin and dexamethasone induction IgA κ, 3.7 g/dL Normal
2. Autologous stem cell transplantation with
high dose melphalan followed by prednisolone
and interferon maintenance
3. Thalidomide
2 1. Vincristine, doxorubicin, methyl prednisolone induction IgG λ, 1.6 g/dL Normal
2. Autologous stem cell transplantation with high dose
melphalan followed by prednisone maintenance
3 1. Vincristine, doxorubicin, and dexamethasone induction IgA κ, 3.9 g/dL Not done
2. Autologous stem cell transplantation with high dose
melphalan
4 1. Melphalan and prednisone IgA λ, 3.2 g/dL Normal
2. Melphalan and prednisone
3. Thalidomide and dexamethasone
5 1. Vinblastine and prednisolone IgG κ, 5.3 g/dL Not done
2. Vincristine, BCNU, melphalan, cyclophosphamide,
prednisone
3. Doxorubicin, melphalan, cyclophosphamide
Table 3 Clinical characteristics
of patients with the MRP1
R723Q polymorphism
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Fig. 1 Time to progression
(panel a), progression-free
survival (panel b), and overall
survival (panel c) of patients
treated for their relapsed and/or
refractory multiple myeloma
with PLD+bortezomib is plotted
based on the presence of either
the A/G or G/G SNP at R723Q
in MRP 1 using the
Kaplan–Meier method
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Discussion
The introduction of novel agents, and their use in rationally
designed combination regimens, has revolutionized the
therapy of multiple myeloma and contributed to an
increasing overall survival [23, 24]. However, myeloma
remains incurable, is still characterized by a decreasing
response duration with each successive salvage therapy [1],
and in the relapsed and especially the refractory settings, is
associated with a median survival of 6 months or less [25].
This behavior is associated in part with the acquisition of a
drug-resistant phenotype [4, 26, 27]. One major mechanism
for this phenotype has been attributed to efflux pumps such
as MDR1 and MRP1, which can reduce the intracellular
drug concentrations of agents used as part of our chemo-
therapeutic armamentarium. Doxorubicin, vincristine, and
etoposide are examples of drugs known to be MDR1 and/
or MRP1 substrates that have activity against myeloma
[28, 29]. This prompted us to examine the possibility that
such SNPs could influence outcomes of myeloma patients
treated with either bortezomib or the PLD+bortezomib
combination.
Fig. 2 Progression-free survival
of patients treated for their
relapsed and/or refractory
multiple myeloma with
PLD+bortezomib is plotted
based on the presence of either
the C/C, C/T, or T/T SNP at
C3435T in MDR1 using the
Kaplan–Meier method
Fig. 3 Time to progression of
patients treated for their relapsed
and/or refractory multiple mye-
loma with PLD+bortezomib is
plotted based on the presence of
the five most common MDR1
diplotypes using the
Kaplan–Meier method
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In the present retrospective study, the MRP1 gene
polymorphism R723Q was significantly associated with
TTP (Fig. 1a), PFS (Fig. 1b), and OS (Fig. 1c) in subjects
who received PLD+bortezomib. Studies of the MRP1
mutation Arg723Gln have not shown that it impacts on
model substrate transport [30], but it does reduce resistance
to agents such as daunorubicin and doxorubicin [19], and
thus it may exert its effect instead through MRP1
expression and trafficking. MRP1 also plays a cytoprotec-
tive role by contributing to the cellular defense system
against oxidative stress [31], possibly through its transport
of glutathione and its conjugates [32]. Since anthracyclines
exert their antitumor effects in part through the induction of
just such stress [33], it may be differences in the ability of
the MRP1 R723Q isoform to play such a role that increased
the sensitivity to PLD+bortezomib, though this hypothesis
will require laboratory testing. Moreover, further studies of
the impact of the MRP1 R723Q allele will be needed to
confirm our findings, given the few subjects with this
genotype that were present in our population.
With regard to MDR1 gene polymorphisms, the SNP at
3435(C>T) was associated with PFS (Fig. 2), and may have
been associated with response rate and TTP in subjects who
received PLD+bortezomib, though not at the level of
statistical significance. Also, haplotype analysis indicated
that the three most frequent haplotypes may have been
associated with the response rate. The most frequent
diplotype that contained 3435 T (i.e., T–W–T/C–G–T or
H2/H3) may have been associated with TTP (p=0.0819) and
PFS (p=0.0891; Fig. 3) in subjects who received PLD+
bortezomib when compared to the most frequent diplotype
(C–G–C/T–W–T or H1/H2), though again not at the level of
statistical significance.
Multidrug resistance genes have previously been identi-
fied as independent prognostic factors for overall survival
in patients with acute myeloid leukemia and multiple
myeloma at diagnosis [14] and relapse [16]. However, this
report suggests that there may be a predictive value of
MDR1 genotypes in modifying the outcome of advanced
myeloma. In particular, in the MDR1 C3435T SNP, the T/T
allele has been found to be associated with weaker drug
efflux activity [34]. It is therefore possible that myeloma
cells carrying the T/T allele would experience a greater
level of cytotoxicity from PLD because of less efficient
doxorubicin efflux, resulting in a longer drug exposure than
tumor cells with the C/C or C/T genotype. As such, T/T
allele carriers might be expected to show a better response
to chemotherapy, but additional preclinical and clinical data
would be needed to confirm this possibility [14, 35].
While MDR1 is known to play a relevant role in the
efflux of anthracyclines, the possibility that it plays a
similar role with respect to bortezomib efflux still needs to
be clarified. Some preclinical studies have suggested that
bortezomib sensitivity may be influenced by modulation of
the function of these gene products [18, 21]. Others, however,
have not shown any impact on bortezomib of these ATP-
cassette binding proteins [36, 37], and bortezomib has not
been felt to be a substrate for these transporters [38].
Interestingly, our current studies did not reveal an association
between outcomes and MDR1 or MRP1 polymorphisms in
the cohort of patients treated with single-agent bortezomib,
further supporting the likelihood that this proteasome
inhibitor is not an MDR substrate.
In conclusion, our study does indicate that MDR1 and
MRP1 polymorphisms may influence outcomes of patients
with relapsed and/or refractory myeloma receiving PLD+
bortezomib. If confirmed by prospective studies, these data
suggest the possibility that such SNP analysis could be used to
identify patients with an increased likelihood of benefiting
from this rationally designed regimen. Using such
approaches, it may be possible in the future to tailor therapy
in the relapsed and/or refractory setting to each individual
based not only on the molecular characteristics of their
disease, but also on the patient’s own genetic makeup.
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